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Introduction
Extracellular adenosine (Ado) is the endogenous ligand of
membrane receptors belonging to the P1 purinergic receptor
family and classified as A1, A2A, A2B and A3 subtypes (A1/A3 and
A2A/A2B are coupled to Gi and Gs protein signalling, respective-
ly).[1] These proteins, named adenosine receptors (ARs), regu-
late many physiological and pathological functions in the cen-
tral nervous system (CNS) and the periphery and are potential
drug targets for diseases such as cardiovascular and immune
disorders, renal failure, inflammatory conditions, and neurologi-
cal, psychiatric and neurodegenerative disorders.[2] As a conse-
quence, a number of medicinal chemistry and pharmacology
studies on AR ligands have been reported by industry or aca-
demic research groups, which have led to the discovery and
development of compounds with potential applications as
drugs. The A2A AR is the target subtype for which the first AR
ligand has been approved for market (the selective agonist Re-
gadenoson, commercialised as Lexiscan by the Astellas Pharma
Company, for myocardial perfusion imaging).[3] This protein is
of particular interest for its roles in the CNS and in neurodege-
nerative disorders, that is, Parkinson’s disease, and selective an-
tagonists of the A2A AR are currently being developed for ther-
apeutic applications. The recent approval for manufacturing
and marketing of the A2A AR selective antagonist Istradefylline
by Nouriast, Kyowa Hakko Kirin Co., Ltd. , in Japan represents
the first authorisation to the market of an AR antagonist as an
anti-parkinsonian agent.[4]
In many papers, we have described the effect of the intro-
duction of substituents at the 2-, 8- and 9-position on the ade-
nine scaffold for the affinity and selectivity of the four AR sub-
types.[5] In particular, the substitution of the ribose moiety of
the natural agonist Ado with an ethyl group leads to the com-
pound 9-ethyladenine, which behaves as an AR antagonist en-
dowed with micromolar affinity for the human A1 and A2A AR
subtypes (inhibition constants KiA1=7440 nm, KiA2A=
2200 nm). However, this molecule is not able to bind the A2B
and A3 ARs at concentrations up to 100 mm. Further modifica-
tion by introduction of a bromine atom in the 8-position of
this molecule led to 8-bromo-9-ethyladenine, a compound that
shows enhanced affinity at all receptor subtypes. This com-
pound behaves as an A2A AR receptor antagonist and is en-
dowed with moderate selectivity, especially against the A1 AR
subtype.[5a] Similarly, the introduction of an 8-bromo substitu-
ent led to a general improvement in the A2A AR affinity for
a series of adenine derivatives substituted in the 9-position
with different alkyl groups.[5g] From investigation of the other
positions of the purine core, it was found that the presence of
a hindered phenethylamino or a phenylethyloxy group in the
2-position of 9-ethyladenine favours the interaction of the re-
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sultant compound with all ARs.[5d] Even in this case, the addi-
tional introduction of an 8-bromo substituent enhances the af-
finity for all ARs with an increased A2A AR selectivity.
[5d] Further-
more, a study on AR agonists showed that the introduction of
arylalkylthio groups in the 2-position of Ado leads to com-
pounds presenting nanomolar affinity for the ARs with a fair
selectivity for the A2A AR.
[6] We also recently reported a series
of 2-alkylamino-substituted 9-propyladenine derivatives that
showed that the different length of the alkyl spacer (methyl to
propyl) within the substituent at the 2-position has the effect
to modulate the affinity for the different AR subtypes.[7] On
this basis, in the search for novel A2A AR antagonists, we de-
signed and synthesised compounds 4–9 and 11–20, which
consist of 9-ethyladenine and 8-bromo-9-ethyladenine ana-
logues bearing, in the 2-position, phenylalkylamino, phenyl-
akyloxy or phenylakylthio groups of various lengths and flexi-
bilities (Schemes 1–4, Table 1 below). The new compounds
were tested in binding assays with human recombinant A1, A2A
and A3 ARs and in a functional cyclic adenosine monophos-
phate (cAMP) assay with the human recombinant A2B AR. Func-
tional studies with the GloSensor cAMP assay were per-
formed to assess the antagonist profile of selected synthesised
derivatives. Furthermore, molecular modelling studies were
performed to interpret and explain the affinity of the newly
synthesised adenine derivatives at the A2A AR.
Results and Discussion
Chemistry
The new 2-substituted 9-ethyladenine derivatives (4, 6, 7, 9,
11–20) were synthesised from commercially available 2,6-di-
chloropurine (1), which was initially treated with iodoethane in
the presence of potassium carbonate as a catalyst and N,N-di-
methylformamide (DMF) as a solvent (Scheme 1).[8] Compounds
5 and 8 were previously reported and were synthesised from
9-ethyl-2-iodoadenine (10).[5a]
The reaction of 2 with liquid ammonia at room temperature
led to 2-chloro-9-ethyladenine (3) in 93% yield. 2-Chloro-9-eth-
yladenine (3) was used for the preparation of the 2-phenylalky-
lamino- and 2-phenylalkyloxy-9-ethyladenines (Scheme 2). For
the synthesis of the 2-thio derivatives, 9-ethyl-2-iodoadenine
(10)[5a] was used as the starting material (Scheme 3).
The synthesis of 2-aminoadenine derivatives 4 and 6 was
performed through the reaction of 3 with the suitable amine
used as a solvent and with heating of the reaction mixture at
high temperature (T=130 8C) for about 24 h. The 2-alkoxyade-
nine derivatives 7 and 9 and the 2-thioadenine analogues 11
and 12 were obtained by using the suitable alcohol or thiol as
a solvent in alkaline catalytic conditions, by addition of NaOH,
at high temperature (T=85–105 8C) for 3–4 h reaction time.
The 2-substituted adenine derivatives 4–9, 11 and 12 were,
in turn, treated with N-bromosuccinimide (NBS) in DMF at
room temperature to introduce a bromine atom at the 8-posi-
tion of the purine ring, which led to the corresponding 8-
bromo derivatives 13–20 (Scheme 4). The reactions were com-
plete within 20–50 min, depending on the substituent present
in the 2-position; the 2-thio derivatives 11 and 12 were the
least reactive in the series. With respect to the synthesis of the
2-unsubstituted adenines reported previously, the reaction
takes a relatively shorter time, which demonstrates the higher
reactivity as a result of the presence of the substituent at the
2-position.[5g]
Biological evaluation
The synthesised compounds were tested in a radioligand bind-
ing assay with human recombinant ARs, expressed in Chinese
hamster ovary (CHO) cells, to evaluate their affinity for the A1,
Scheme 2. Preparation of 2-phenylalkylamino- and 2-phenylalkyloxy-9-ethyl-
adenines. Reagents and conditions : RNH2, 130 8C, 24–28 h or ROH, NaOH, 85–
105 8C, 3–4 h.
Scheme 3. Preparation of 2-phenylalkylthio-9-ethyladenines. Reagents and
conditions : RSH, NaOH, 100 8C, 24 h.
Scheme 4. Preparation of 8-bromo-substituted adenines. Reagents and con-
ditions : NBS, DMF, RT, 20–50 min.
Scheme 1. Preparation of 2-chloro-9-ethyladenine (3). Reagents and condi-
tions : a) K2CO3, CH3CH2I, DMF, RT, 6 h; b) NH3, RT, 20 h.
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A2A and A3 AR subtypes. [
3H]-2-chloro-N6-cyclopentyladenosine
(CCPA), [3H]-5’-N-ethylcarboxamidoadenosine (NECA) and [3H]-
2-hexyn-2-yl-N6-methyladenosine (HEMADO) were used as the
respective radioligands.[9] The results are reported as Ki values
in nanomolar, with 95% confidence intervals in parentheses
(Table 1). The Ki values at the A2B AR were calculated from the
half-maximal inhibitory concentration (IC50) values determined
from analysis of the inhibition of NECA-stimulated adenylyl cy-
clase activity (Table 1).[9a] The derivatives 9-ethyladenine and 8-
bromo-9-ethyladenine are reported in Table 1 as reference
compounds, together with the already reported compounds 5,
8, 14 and 17. As mentioned above, 9-ethyladenine shows mi-
cromolar affinity for the A1 and A2A ARs but is not able to bind
the A2B and A3 ARs, even at high concentrations (9-ethylade-
nine: KiA1=7440 nm ; KiA2A=2200 nm ; KiA2B>30000 nm ;
KiA3>100000 nm).
The introduction of a bromine atom in the 8-position or
a phenylethylamino or phenylethyloxy group in the 2-position
of 9-ethyladenine leads to compounds with improved affinity
at all ARs with some selectivity for the A2A AR subtype (8-
bromo-9-ethyladenine: KiA2A=52 nm ; A1/A2A=5; 5 : KiA2A=
150 nm ; A1/A2A=2; 8 : KiA2A=120 nm ; A1/A2A=1). Notably, the
combination of these substitutions in the 8- and 2-positions
gives further improvement of affinity (14 : KiA1=150 nm ;
KiA2A=19 nm ; KiA2B=690 nm ; KiA3=3100 nm ; 17: KiA1=23 nm ;
KiA2A=1.7 nm ; KiA2B=569 nm ; KiA3=1090 nm), with compound
Table 1. Biological activity of synthesised compounds at human adenosine receptors stably transfected in CHO cells.
Compd R1 R2 Ki [nm]
[a]
A1 AR
[b] A2A AR
[c] A2B AR
[d] A3 AR
[e]
9-ethyladenine[5a] 7440
(4220–13120)
2200
(1400–3530)
>30000 >100000
8-bromo-9-ethyladenine[5a] 280
(250–320)
52
(24–110)
840
(630–1100)
28000
(22000–35000)
4 PhCH2NH H 1130
(646–1970)
708
(388–1290)
>30000 10000
13 PhCH2NH Br 220
(170–290)
33
(21–50)
710
(230–2200)
590
(330–1000)
5[5d] Ph(CH2)2NH H 330
(250–510)
150
(110–210)
2400
(1400–4000)
3200
(2400–4100)
14[5d] Ph(CH2)2NH Br 150
(120–180)
19
(5.8–60)
690
(250–1900)
3100
(1000–6600)
6 Ph(CH2)3NH H 1670
(1490–1870)
1690
(1580–1800)
>30000 18300
(16500–20300)
15 Ph(CH2)3NH Br 223
(196–253)
53
(42–66)
6990
(4580–10700)
4560
(3460–6020)
7 PhCH2O H 1010
(698–1460)
113
(83–154)
14600
(9890–21600)
2620
(2170–3160)
16 PhCH2O Br 143
(104–196)
6.8
(6.3–7.4)
1500
(1080–2080)
408
(380–438)
8[5d] Ph(CH2)2O H 170
(130–230)
120
(70–220)
45800
(29800–70500)
7150
(2950–17300)
17[5d] Ph(CH2)2O Br 23
(23–24)
1.7
(1.4–2.2)
569
(440–734)
1090
(685–1720)
9 Ph(CH2)3O H 736
(587–922)
738
(641–851)
>30000 13200
(11200–15600)
18 Ph(CH2)3O Br 58
(48–70)
22
(14–33)
>30000 >100000
11 PhCH2S H 1160
(1090–1230)
1530
(976–2390)
>30000 7220
(5750–9060)
19 PhCH2S Br 96
(90–102)
53
(49–58)
3200
(2740–3730)
605
(579–633)
12 Ph(CH2)2S H 897
(827–973)
470
(311–710)
>30000 6040
(5010–7300)
20 Ph(CH2)2S Br 95
(72–125)
16
(9.2–26)
6526
(5487–7727)
3601
(2960–4390)
[a] 95% confidence intervals are given in parentheses. [b] Displacement of specific [3H]CCPA binding in CHO cells stably transfected with human recombi-
nant A1 AR. [c] Displacement of specific [
3H]NECA binding in CHO cells stably transfected with human recombinant A2A AR. [d] Ki values at the A2B AR were
calculated from IC50 values determined by inhibition of NECA-stimulated adenylyl cyclase activity. [e] Displacement of specific [
3H]HEMADO binding in CHO
cells stably transfected with human recombinant A3 AR.
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17 presenting the highest A2A AR affinity and selectivity (A1/
A2A=14).
[5d] We tested the effect of the introduction of a phe-
nylalkylthio group of the same length in the 2-position of 9-
ethyladenine and the further modification by introduction of
a bromine atom in the 8-position (12 and 20, respectively).
Even these modifications on 9-ethyladenine give an improve-
ment in AR affinity, with a slight selectivity for the A2A AR main-
tained (12 : KiA2A=470 nm ; 20 : KiA2A=16 nm), with the excep-
tion of compound 12 at the A2B AR. Compound 20 is even
more active at the A2A AR than the corresponding 2-phenyle-
thylamino analogue 14. The next step was to evaluate the
effect of the variation of the length of the alkyl spacer within
the 2-substituent. With consideration of the 2-arylalkylamino
series, the modification of the ethyl spacer of the 2-substituent
of 5 with a shorter methyl group leads to a decrease in AR af-
finity and A2A AR selectivity. The substitution of the ethyl
spacer with a propyl chain leads to an almost identical affinity
at the A2A and A1 ARs (6 : KiA1=1670 nm ; KiA2A=1690 nm).
With regard to the 2-arylalkyloxy series, the modification of the
ethyl spacer of the 2-substituent of 8 with a shorter methyl
group has the effect of improving the affinity for almost all
ARs and particularly the selectivity for the A2A AR relative to
the A1 AR (7: KiA2A=113 nm ; A1/A2A=9). The substitution of
the same ethyl spacer with a propyl chain decreases the affini-
ty for all ARs and leads to an almost identical affinity for the
A2A and A1 ARs (9 : KiA1=736 nm ; KiA2A=738 nm). Finally, the
affinity for the ARs shown by the 2-phenylalkylthio-substituted
derivative 12 is decreased if its ethyl spacer is substituted by
a shorter methyl group (11). The latter compound is also not
selective for the A2A AR.
As expected, further modification of these compounds with
the introduction of a bromine atom in the 8-position leads to
molecules that present generally improved affinity at all of the
ARs with respect to the corresponding 8-unsubstituted ana-
logues. With consideration of the 2-arylalkylamino series, com-
pounds 13 and 15 present a 20–30-fold increase of affinity at
the A2A AR with respect to the corresponding 8-unsubstituted
analogues (4 and 6, respectively) and also show a fair selectivi-
ty versus the A1 AR (13 : KiA2A=33 nm ; A1/A2A=6.7; 15 : KiA2A=
53 nm ; A1/A2A=4.2). It must also be noted that compound 13
presents an interesting affinity at the A2B and A3 ARs (13 :
KiA2B=710 nm ; KiA3=590 nm). In any case, we do not observe
an improvement of affinity and selectivity in this series with re-
spect to those already reported for compound 14. With regard
to the 2-arylalkyloxy set of compounds, the introduction of
a bromine atom in the 8-position of 7 and 9 (16 and 18, re-
spectively) again improves the affinity for the A2A AR. Com-
pound 16 is endowed with low nanomolar affinity at the A2A
AR (16 : KiA1=143 nm ; KiA2A=6.8 nm ; KiA2B=1500 nm ; KiA3=
408 nm) and the best selectivity profile against the A1 AR
(about 21-fold), with a significant improvement relative to the
already reported compound 17 that is its superior homologue.
Interestingly, in the case of the 8-bromo-2-phenylpropyloxy-
substituted derivative 18, we observe a complete loss of affini-
ty for the A3 AR and the affinity for the A2BAR is not improved
relative to the 8-unsubstituted analogue 9. Finally, in consider-
ation of the 2-arylalkylthio series, the introduction of a bromine
atom in the 8-position of 11 leads to compound 19, which
presents an improved affinity for all ARs and an interesting Ki
value for the A3 AR. The selectivity for the A2A AR is very low,
particularly relative to the A1 AR subtype.
If the results are taken together, the new 2-substituted com-
pounds display, in general, Ki values ranging from micromolar
to high nanomolar concentrations for all ARs, with more pro-
nounced affinity for the A2A and A1 AR subtypes, whereas (as
observed in previous reports) the corresponding 8-bromo-sub-
stituted derivatives show generally increased affinity at all ARs
relative to the corresponding 8-unsubstituted derivatives. The
2-arylalkyloxy substituents appear, in general, to provide
higher affinity with respect to the corresponding 2-alkylamino
or 2-alkylthio groups. The optimal alkyl spacer of the 2-sub-
stituent is the methylene or ethyl group beside the heteroa-
tom, whereas the affinity significantly decreases with a propyl
linker. The already reported compound 14 and the new com-
pound 16 present the highest A2A AR affinity and selectivity
(versus the A1 AR), respectively, among all of the presented
compounds.
To evaluate the functional activity of the new derivatives,
representative compounds 14, 16, 17 and 20, which showed
high A2A AR affinity, were evaluated with the GloSensor
cAMP assay.[10] The full AR agonist NECA and the A2A AR antag-
onist 8-bromo-9-ethyladenine were tested as reference com-
pounds. The results of this analysis are reported in Table 2. As
expected, the reference compound NECA behaved as a full ag-
onist with potency comparable to that reported in literature.[11]
By contrast, 8-bromo-9-ethyladenine, the antagonistic behav-
iour of which has been demonstrated in different in vivo
models of Parkinson’s disease,[12] behaved as an antagonist.
The new compounds 14, 16, 17 and 20 were unable to acti-
vate the A2A AR when tested alone (data not shown), whereas
they counteracted, to different extents, the effect of the full
agonist NECA and behaved as A2A AR antagonists. Further-
more, they showed a very similar trend of activity to the bind-
ing data, with 8-bromo-9-ethyl-2-phenylethyloxyadenine (17;
IC50=5.6 nm) presenting the highest potency at the human
A2A AR.
Table 2. Functional activity at the human A2A AR expressed in CHO cells
transiently transfected with firefly luciferase biosensor by using the Glo-
Sensor cAMP assay. Binding data are reported for comparison.
Compd EC50 [nm]
[a] IC50 [nm]
[b] Ki [nm]
NECA 12540 – –
8-bromo-9-ethyladenine – 8328 52
14 – 377 19
17 – 5.61 1.7
20 – 4812 16
16 – 123 6.8
[a] Concentration of agonist required to produce 50% of the maximum
effect. [b] Concentration of antagonists that produces 50% inhibition of
the agonist effect. Each concentration was tested five times in triplicate,
and values are given as the mean  standard error.
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Molecular modelling
A molecular modelling study was performed to simulate and
analyse the interaction of the synthesised molecules with the
binding site of the human A2A AR. For this analysis, two crystal
structures of the same protein solved in complex with
ZM241385 antagonist (Protein Data Bank (PDB) ID: 3EML for
2.6  resolution and PDB ID: 4EIY for 1.8  resolution[13]) were
employed. The 3EML crystal structure was re-modelled by re-
moving the external T4L segment and by performing a building
of missing receptor regions (the missing section of the extra-
cellular 2 (EL2) or intracellular 3 (IL3) domains). The quality of
the obtained A2A AR model was checked within the Molecular
Operating Environment (MOE, version 2010.10) suite.[14] The
two A2A AR structures were then employed as molecular tar-
gets for docking analysis of developed compounds. All ligand
structures were geometrically optimised with RHF/AM1 semi-
empirical calculations (by using the MOPAC[15] software imple-
mented in the MOE suite) and then subjected to docking anal-
ysis into the binding site of the human A2A AR model by using
AutoDock 4.2.6 software and the PyRx interface.[16] Docking re-
sults were then imported into the MOE suite for post-docking
analysis. The 2- and 2,8-substituted 9-ethyladenine derivatives
present structural similarities with the co-crystallised
ZM241385 compound and, as observed in previous docking
studies of adenine derivatives at the A2A AR,
[5e,7,17] the docking
results for these new molecules show a general binding mode
that is comparable to that of the A2A AR reference ligand (ob-
served in the 3EML and 4EIY crystal structures). In detail
(Figure 1, docking at the 3EML structure), the adenine scaffold
of the compound is vertically orientated and positioned be-
tween residues of the EL2 and transmembrane (TM) 6 domains
(Phe168 and Leu2496.51,[18] respectively), which is similar to the
position and orientation of the triazolotriazine scaffold of
ZM241385 and of the same purine observed from the binding
mode of the nucleoside Ado within another A2A AR crystal
structure (PDB ID: 2YDO[19]). The 6-amino group and the N7 ni-
trogen atom of adenine give a double hydrogen bond interac-
tion with the Asn2536.55 residue, whereas the 9-ethyl group is
located between residues of the TM3, TM5 and TM6 domains
(Leu853.33, Met1775.38, Trp2466.48).
With consideration of the substituent at the 2-position, as
recently observed for a series of 2-substituted 9-propylade-
nines,[7] an alkyl spacer of one or two carbon atoms within this
group leads to high affinity, whereas a longer chain seems
generally detrimental for the binding activity. The binding
mode suggested by the docking results presents the 2-sub-
stituent pointing toward the extracellular space, with the
phenyl ring located between EL2 and EL3 residues (Figure 1A).
In the case of a propyl linker, the phenyl ring is externally lo-
cated and, hence, is exposed to the solvent. Figure 1B shows
the binding cavity and compound 7 represented as molecular
surfaces. This representation highlights the partial exposure to
the extracellular environment of the phenyl ring within the 2-
substituent. Some docking conformations also present the 2-
substituent orientated towards residues belonging to the TM1,
TM2 and TM3 domains but only for the derivatives containing
a methyl or ethyl spacer within this group (Figure 1C). This
could be a factor explaining the generally lower affinity of
compounds bearing a propyl spacer within the 2-substituent.
In consideration of the effect of the heteroatom within the
same group, the binding data highlight the generally higher
affinity of the 2-alkoxy-substituted derivatives relative to the
corresponding 2-alkylamino- and 2-alkylthio-substituted ana-
logues. The 2-amino group of the 2-alkylamino series is conju-
gated to the aromatic purine scaffold and makes part of the 2-
substituent co-planar to the scaffold itself, which provides sig-
nificantly higher rigidity to these derivatives than to the 2-
alkoxy analogues. In this sense, the higher flexibility of the
latter derivatives could make these molecules more able to be
accommodated within the binding cavity. This is particularly
evident for the compounds bearing a methyl spacer within the
2-substituent (see the binding data of 7 and 16 for the 2-
alkoxy series and 4 and 13 as the corresponding 2-alkylamino
analogues; Table 1). In the case of derivatives containing an
Figure 1. Docking conformations of analysed compounds at the A2A AR.
A) Binding mode of compound 9, with an indication of the key ligand–re-
ceptor interaction residues. B) Representation of the same binding mode as
a molecular surface; the cavity and ligand surfaces are represented as yellow
and red, respectively. C) Binding mode of compound 16.
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ethyl spacer in the 2-position, the difference in flexibility be-
tween the two series would be less evident.
The presence of an 8-bromo substituent significantly im-
proves the affinity for the A2A AR relative to the corresponding
8-unsubstituted derivatives. The docking results show the bro-
mine atom as orientated towards the receptor core and locat-
ed between residues of the TM3, TM5 and TM6 segments
(Leu853.33, Thr883.36, Met1775.38, Trp2466.48, Leu2496.51 and
His2506.52). We hence performed a further analysis of the inter-
actions between the compounds and the receptor binding site
by using the IF-E 6.0[20] tool that is available from the SVL ex-
change service (Chemical Computing Group, Inc.) and that we
previously employed for other analyses with ARs.[21] The script
calculates and displays atomic and residue interaction forces
as 3D vectors. It also calculates the per-residue interaction en-
ergies (values in kcalmol1), for which negative and positive
energy values are associated to favourable and unfavourable
interactions, respectively. Our analysis was focused on the in-
teraction between the compounds and the residues located in
the proximity of the 8-position. For this task, we employed the
three 8-unsubstituted derivatives 5, 8 and 12 and the corre-
sponding 8-bromo-substituted analogues 14, 17 and 20, re-
spectively.
The results of this analysis are in good agreement for the
two employed receptor structures and are reported in Tables 3
and 4 (for the docking results at the 3EML and 4EIY A2A AR
structures, respectively). The data indicate that, in general, the
8-bromo-substituted compounds present a more favourable
interaction with the binding site residues (located in the prox-
imity of the 8-position) than the 8-unsubstituted derivatives,
even if the difference between the respective estimated
energy values is not large. These data could suggest that the
role of the 8-bromo substituent might not be exclusively relat-
ed to its interaction with the receptor. An additional role of
this substituent could be possibly related to its ability to fill
the TM3–TM5–TM6 hydrophobic sub-cavity and, hence, to pro-
vide the compounds with better steric properties to fit the
binding cavity. Figure 2 represents both the binding cavity of
the 3EML A2A AR and the binding mode of compounds 7 and
16 as molecular surfaces for comparison. From this figure, it is
possible to observe the different occupancy of the 8-bromo-
substituted derivative 16 relative to the unsubstituted ana-
logue 7, in particular in the sub-cavity created by the TM3,
TM5 and TM6 residues.
Table 4. Interaction energies between compounds 5, 14, 8, 17, 12 and
20 and the binding site residues located in the proximity of the 8-posi-
tion of the analysed compounds. Data are related to the 4EIY A2A AR
structure. See the text for details.
Residue Einteract. [kcalmol
1]
5 14 8 17 12 20
Val84 0.73 0.38 0.29 0.2 0.31 0.22
Leu85 0.29 1.36 1 1.39 0.95 1.29
Thr88 0.01 0.79 0.6 0.78 0.6 0.81
Phe168 2.58 3.88 2.17 3.87 3.2 4.19
Met177 0.61 0.08 1.33 0.16 0.35 0.14
Trp246 0.49 0.62 0.23 0.73 0.21 0.54
Leu249 2.24 0.01 1.17 0.67 1.54 0.85
His250 0.07 0.41 0.17 0.39 0.12 0.36
Asn253 2.52 4.02 2.88 3.99 2.6 3.26
total 9.54 11.53 9.84 11.86 9.88 11.66
Table 3. Interaction energies between compounds 5, 14, 8, 17, 12 and
20 and the binding site residues located in the proximity of the 8-posi-
tion of the analysed compounds. Data are related to the 3EML A2A AR
structure. See the text for details.
Residue Einteract. [kcalmol
1]
5 14 8 17 12 20
Val84 1.13 1.15 0.57 0.33 0.90 1.42
Leu85 0.028 0.53 1.40 1.74 0.03 0.38
Thr88 0.20 0.07 0.42 0.69 0.21 0.01
Phe168 3.77 3.61 2.03 4.12 3.37 2.95
Met177 0.54 1.26 0.79 0.89 0.34 1.05
Trp246 0.14 0.67 1.78 0.33 0.33 0.89
Leu249 2.45 2.94 1.44 0.33 2.06 2.41
His250 0.52 0.76 0.29 1.30 0.62 0.97
Asn253 4.01 4.23 3.26 2.68 3.62 4.42
total 12.33 15.23 8.41 11.74 11.01 14.47
Figure 2. Docking conformations of analysed compounds at the A2A AR.
Binding modes of compounds 7 (A) and 16 (B), with representations as mo-
lecular surfaces; the cavity and ligand surfaces are represented as yellow
and red, respectively.
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The selectivity of the synthesised molecules appears not to
be very high, particularly versus the A1 AR. We therefore per-
formed a docking analysis of a selected group of ligands (17
and 18, which present 23 and 58 nm A1 AR affinity, respective-
ly) with a homology model of this receptor built by using the
4EIY A2A AR crystal structure as a template. The results of this
analysis present the compounds inserted in the receptor cavity
with a similar binding mode to the one retrieved at the A2A AR
(Figure 3). The residues involved in the interaction with the li-
gands are quite conserved between the A1 AR and the A2A AR,
particularly within the binding cavity. Some differences are ob-
served with regard to the residues at the entrance of the
cavity and in the proximity of the 2-substituent. In detail, the
three hydrophobic amino acids of the A2A AR, Leu167 (EL2),
Leu267 (EL3) and Met270 (TM7), are substituted in the A1 AR
by the polar residues Glu170 (EL2), Ser267 (EL3) and Thr270
(TM7), respectively. Hence, in the case of the compounds pre-
senting a short 2-substituent, the chemical–physical profile of
the receptor residues located in the proximity of this group ap-
pears to be significant. By contrast, the compounds presenting
a long 2-substituent (and endowed in general with low AR af-
finity) may more easily adapt their conformation, even to the
A1 AR, and optimise their interaction with the surrounding resi-
dues. This would explain the reduced (or non-existent) A2A AR
selectivity of the compounds presenting a propyl spacer
within the 2-substituent. More data are needed to confirm this
hypothesis, because in the case of the 2-thio-substituted com-
pounds it appears that the shorter chain causes a slight prefer-
ence for the A1 AR.
Conclusions
This work describes a series of 2-substituted 9-ethyladenine
derivatives and their corresponding 8-bromo-substituted ana-
logues, designed and synthesised as novel AR ligands with the
aim to obtain high affinity and selectivity, in particular for the
A2A AR subtype. They present phenylalkyloxy, phenylalkylamino
or phenylalkylthio groups of different lengths at the 2-position.
The compounds were tested with human ARs in a radioligand
binding assay (A1, A2A, and A3 AR subtypes) and evaluated for
their ability to modulate the adenylyl cyclase activity (A2B ARs).
The results show that the derivatives are endowed with nano-
molar affinity for the ARs. This activity is higher if the alkyl
spacer within the 2-substituent is one or two carbon atoms
long and if the additional 8-bromo substituent is present. The
2-arylalkyloxy-substituted compounds present generally higher
affinity than the corresponding 2-arylalkylamino- or 2-arylal-
kylthio-substituted analogues. Although the already reported
compound 8-bromo-9-ethyl-2-phenylethyloxyadenine (17) re-
mains the antagonist endowed with the highest affinity for the
A2A AR subtype, it should be noted that one of the newly syn-
thesised derivatives presents low nanomolar A2A AR affinity
and improved selectivity versus the A1 AR subtype (16 : KiA2A=
6.8 nm ; A1/A2a=21; versus 17: KiA2A=1.7 nm ; A1/A2a=14).
Functional studies, performed with representative molecules,
confirmed that the new compounds behave as antagonists of
the human A2A AR with IC50 values in the nanomolar range, in
agreement with the binding data. Molecular modelling studies
were performed to provide an interpretation of the different
affinities of the compounds at the A2A AR, with particular con-
sideration of the roles of the substituents introduced on the
adenine moiety. The results highlight that the presence of the
8-bromo substituent helps the ligands to fit the receptor cavity
with higher topological complementarity than the 8-unsubsti-
tuted derivatives. These data suggest that the modulation of
the 8-substituent volume would further optimise the ligand–
receptor interaction. In this sense, the 8-bromine atom present
in these derivatives allows an easy substitution by other moiet-
ies or functional groups. Furthermore, the different lengths of
the 2-substituent leads to various affinities for the A2A AR. In
this sense, the compounds presenting longer 2-substituent
chains would make the phenyl ring of this substituent more
externally exposed causing an unfavourable interaction with
the solvent. Further optimisation of these derivatives could
lead to the modulation of the 2-substituent length combined
with the modification of the phenyl ring or the insertion of
polar groups at this moiety. This work makes available novel
data that are useful for the design and synthesis of A2A AR li-
gands based on the adenine scaffold and containing arylalkyl
chains in the 2-position, with possible combination with fur-
ther substituents in the 8-position.
Experimental Section
Chemistry
General : Melting points were determined with a Bchi apparatus
and are uncorrected. 1H NMR spectra were obtained with a Varian
Mercury 400 MHz spectrometer; d values are in ppm, J values are
in Hz. All exchangeable protons were confirmed by the addition of
D2O. Thin-layer chromatography (TLC) was carried out on pre-
coated TLC plates with silica gel 60 F254 (Fluka). For column chro-
matography, silica gel 60 (Merck) was used. Elemental analyses
were determined on a Fisons Instruments Model EA 1108 CHNS-O
model analyser and are within 0.4% of theoretical values. The
Figure 3. Docking conformation of compound 17 at the A1 AR receptor
model with detail of the receptor residues located at the entrance of the
binding cavity.
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purity of the compounds was 95% according to the elemental
analysis data.
General procedure for the synthesis of the 9-ethyl-2-phenyl-
alkylaminoadenine derivatives 4 and 6 : 2-Chloro-9-ethyladenine
(3 ; 200 mg, 1.0 mmol) and the suitable amine (3.5 mL) were placed
in a steel vial and heated at 130 8C for 24–28 h until completion of
the reaction. The volatiles were then removed in vacuo and the
residue was subjected to chromatography on a silica gel column
with elution with the suitable solvent system to obtain compounds
4 and 6 as white solids.
N2-Benzyl-9-ethyl-9H-purine-2,6-diamine (4): Obtained by the re-
action of 3 with benzylamine in a 28 h reaction time and by purifi-
cation with normal column chromatography with elution with
CHCl3/CH3OH (95:5); yield 65%; mp: 169–173 8C;
1H NMR
([D6]DMSO): d=1.31 (t, 3H, J=7.2 Hz, CH2CH3), 3.97 (m, 2H,
CH2NH), 4.48 (q, 2H, J=7.2 Hz, CH2CH3), 6.65 (br s, 2H, NH2), 6.79 (t,
2H, J=5.6 Hz, NH), 7.14–7.37 (m, 5H, HPh), 7.71 ppm (s, 1H, H8);
elemental analysis: calcd for C14H16N6: C 62.67, H 6.01, N 31.32,
found: C 62.78, H 6.16, N 31.21.
9-Ethyl-N2-(3-phenylpropyl)-9H-purine-2,6-diamine (6): Obtained
by the reaction of 3 with 1-propylamine in a 24 h reaction time
and by purification with flash column chromatography with elution
with CHCl3/CH3OH (98:2); yield 70%; mp: 65–70 8C;
1H NMR
([D6]DMSO): d=1.35 (t, 3H, J=7.2 Hz, CH2CH3), 1.83 (m, 2H,
CH2CH2CH2), 2.64 (t, 2H, J=7.2 Hz, CH2Ph), 3.27 (m, 2H, CH2NH),
3.99 (q, 2H, J=7.2 Hz, CH2CH3), 6.30 (t, 1H, J=5.6 Hz, NH), 6.59
(br s, 2H, NH2), 7.25 (m, 5H, HPh), 7.71 ppm (s, 1H, H8); elemental
analysis: calcd for C16H20N6: C 64.84, H 6.80, N 28.36, found: C
64.97, H 6.87, N 28.29.
General procedure for the synthesis of the 9-ethyl-2-phenylal-
koxyadenine derivatives 7 and 9 : Anhydrous NaOH (200 mg,
5 mmol) was added to a mixture of 2-chloro-9-ethyladenine (3)
(200 mg, 1.0 mmol) suspended in the suitable alcohol (9.0 mL). The
mixture was heated at 85–105 8C for 3–4 h. The solvent was then
removed in vacuo and the residue was suspended in H2O, neutral-
ised with 2n HCl and then partitioned with CHCl3 three times. The
combined organic layers were dried over anhydrous Na2SO4, fil-
tered and concentrated in vacuo. Compounds 7 and 9 were ob-
tained after purification with silica gel flash column chromatogra-
phy with elution with the appropriate solvent system.
2-Benzyloxy-9-ethyl-9H-purin-6-amine (7): Obtained by reaction
of 3 with benzyl alcohol in a 4 h reaction time and by column
chromatography with elution with CHCl3/CH3OH (95:5); yield 49%;
white solid (cryst. CH3OH); mp: 168–170 8C;
1H NMR ([D6]DMSO):
d=1.37 (t, 3H, J=7.2 Hz, CH3), 4.08 (q, 2H, J=7.2 Hz, CH2CH3), 5.32
(s, 2H, OCH2Ph), 7.25 (s, 2H, NH2), 7.34–7.50 (m, 5H, HPh),
7.98 ppm (s, 1H, H8); elemental analysis: calcd for C14H15N5O: C
62.44, H 5.61, N 26.01, found: C 62.57, H 5.71, N 25.92.
9-Ethyl-2-(3-phenylpropoxy)-9H-purin-6-amine (9): Obtained by
the reaction of 3 with 1-propylalcohol in a 4 h reaction time and
by column chromatography with elution with CHCl3/CH3OH (95:5);
yield 83%; white solid (cryst. CH3CN); mp: 131–133 8C;
1H NMR
([D6]DMSO): d=1.38 (t, 3H, J=7.2 Hz, CH3), 2.00 (m, 2H, CH2CH2O),
2.74 (t, 2H, J=7.06 Hz, CH2Ph), 4.07 (q, 2H, J=7.2 Hz, CH2CH3),
4.22 (t, 2H, J=6.4 Hz, CH2O), 7.13–7.37 (m, 7H, HPh and NH2),
7.96 ppm (s, 1H, H8); elemental analysis: calcd for C16H19N5O: C
64.63, H 6.44, N 23.55, found: C 64.68, H 6.55, N 23.43.
General procedure for the synthesis of the 9-ethyl-2-phenylal-
kylthioadenine derivatives 11 and 12 : A suspension of 2-iodo-9-
ethyladenine (10 ; 289 mg, 1.0 mmol) in the suitable thiol (5.8 mL)
and anhydrous NaOH (280 mg) was placed in a steel vial in an
oven at 100 8C for 24 h. The volatiles were then removed in vacuo
and the residue was suspended in H2O, neutralised with 1n HCl
and partitioned three times with CHCl3. The collected organic
layers were dried over anhydrous Na2SO4, filtered and concentrated
in vacuo. Compounds 11 and 12 were obtained as white solids
after silica gel normal column chromatography with elution with
CHCl3/CH3OH (97:3).
2-(Benzylthio)-9-ethyl-9H-purin-6-amine (11): Obtained by the re-
action of 10 with benzylthiol ; yield 65%; mp: 145–147 8C; 1H NMR
([D6]DMSO): d=1.39 (t, 3H, J=7.2 Hz, CH2CH3), 4.14 (q, 2H, J=
7.2 Hz, CH2CH3), 4.36 (s, 2H, CH2Ph), 7.19–7.44 (m, 7H, HPh and
NH2), 8.04 ppm (s, 1H, H8); elemental analysis: calcd for C14H15N5S:
C 58.93, H 5.30, N 24.54, found: C 59.04, H 5.35, N 24.49.
9-Ethyl-2-(phenethylthio)-9H-purin-6-amine (12): Obtained by the
reaction of 10 with 2-phenethylthiol; yield 77%; mp: 152–154 8C;
1H NMR ([D6]DMSO): d=1.42 (t, 3H, J=7.2 Hz, CH2CH3), 3.00 (m,
2H, CH2Ph), 3.31 (m, 2H, CH2S), 4.16 (q, 2H, J=7.2 Hz, CH2CH3),
7.19–7.24 (m, 7H, HPh and NH2), 8.05 ppm (s, 1H, H8); elemental
analysis: calcd for C15H17N5S: C 60.18, H 5.72, N 23.39, found: C
60.29, H 5.83, N 23.30.
General procedure for the synthesis of the 8-bromo-9-ethyl-2-
substituted adenine derivatives 13–18 : NBS (267 mg, 1.5 mmol)
was added to a solution of either 4–9, 11 or 12 (1.0 mmol) in anhy-
drous DMF (10 mL). The mixture was left under stirring at room
temperature for 20–50 min. The solvent was then removed in va-
cuo and the residue was purified on silica gel normal column chro-
matography with elution with the suitable eluent to obtain the
pure desired products as white solids.
N2-Benzyl-8-bromo-9-ethyl-9H-purine-2,6-diamine (13): Obtained
from 4 ; purified by silica gel normal column chromatography with
elution with CHCl3/CH3OH (98:2); yield 19%; mp: 156–158 8C;
1H NMR ([D6]DMSO): d=1.25 (t, 3H, J=7.3 Hz, CH2CH3), 3.99 (q, 2H,
J=7.3 Hz, CH2CH3), 4.47 (d, 2H, J=6.5 Hz, NHCH2), 6.82 (br s, 2H,
NH2), 6.98 (t, 1H, J=6.5 Hz, NHCH2), 7.13–7.40 ppm (m, 5H, HPh);
elemental analysis: calcd for C14H15BrN6: C 48.43, H 4.35, N 24.20,
found: C 48.52, H 4.44, N 24.13.
8-Bromo-9-ethyl-N2-phenethyl-9H-purine-2,6-diamine (14): Ob-
tained from 5 ; purified by silica gel normal column chromatogra-
phy with elution with EtOAc/C6H12/CH3OH (60:39:1); yield 62%
(cryst. CH3CN/CH3OH); mp: 182–183 8C;
1H NMR ([D6]DMSO): d=
1.30 (t, 3H, J=7.2 Hz, CH2CH3), 2.84 (t, 2H, J=7.5 Hz, NHCH2), 3.45
(m, 2H, CH2Ph), 4.02 (q, 2H, J=7.2 Hz, CH2CH3), 6.45 (m, 1H,
NHCH2), 6. 58 (br s, 2H, NH2), 7.28 ppm (m, 5H, HPh) elemental
analysis: calcd for C15H17BrN6: C 49.87, H 4.74, N 23.26, found: C
49.99, H 4.76, N 23.19.
8-Bromo-9-ethyl-N2-(3-phenylpropyl)-9H-purine-2,6-diamine (15):
Obtained from 6 ; purified by silica gel normal column chromatog-
raphy with elution with cHex/EtOAc/CH3OH (70:29:1) ; yield 54%
(cryst. CH3OH); mp: 122–124 8C;
1H NMR ([D6]DMSO): d=1.28 (t,
3H, J=7.2 Hz, CH2CH3), 1.83 (m, 2H, CH2CH2CH2), 2.64 (t, 2H, J=
7.2 Hz, CH2Ph), 3.27 (m, 2H, CH2NH), 4.00 (q, 2H, J=7.2 Hz,
CH2CH3), 6.49 (t, 1H, J=7.8 Hz, NH), 6.80 (br s, 2H, NH2), 7.24 ppm
(m, 5H, HPh); elemental analysis : calcd for C16H19BrN6: C 51.21, H
5.10, N 22.39, found: C 51.29, H 5.17, N 22.30.
2-(Benzyloxy)-8-bromo-9-ethyl-9H-purin-6-amine (16): Obtained
from 7 with a 20 min reaction time; purified by silica gel flash
column chromatography with elution with cHex/CHCl3/CH3OH
(59:40:1) ; yield 66% (cryst. CHCl3) ; mp: 208–210 8C;
1H NMR
([D6]DMSO): d=1.30 (t, 3H, J=7.0 Hz, CH3), 4.08 (q, 2H, J=7.0 Hz,
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CH2CH3), 5.32 (s, 2H, CH2Ph), 7.30–750 ppm (m, 7H, HPh and NH2);
elemental analysis: calcd for C14H14BrN5O: C 48.29, H 4.05, N 20.11,
found: C 48.34, H 4.11, N 20.09.
8-Bromo-9-ethyl-2-phenethoxy-9H-purin-6-amine (17): Obtained
from 8 with a 45 min reaction time; purified by silica gel flash
column chromatography with elution with EtOAc/cHex/CH3OH
(50:49:1) ; yield 56% (cryst. CH3CN/CH3OH); mp: 169–171 8C;
1H NMR ([D6]DMSO): d=1.28 (t, 3H, J=7.0 Hz, CH2CH3), 2.99 (t, 2H,
J=7.0 Hz, CH2NH), 4.04 (q, 2H, J=7.0 Hz, CH2CH3), 4.39 (t, 2H, J=
7.0 Hz, CH2O), 7.25–7.32 (m, 5H, HPh), 7.37 ppm (br s, 2H, NH2); ele-
mental analysis : calcd for C15H16BrN5O: C 49.74, H 4.45, N 19.33,
found: C 49.80, H 4.48, N 19.31.
8-Bromo-9-ethyl-2-(3-phenylpropoxy)-9H-purin-6-amine (18): Ob-
tained from 9 with a 20 min reaction time; purified by silica gel
flash column chromatography with elution with cHex/CHCl3/
CH3OH (59:40:1); yield 69% (cryst. CH3CN); mp: 181–183 8C;
1H NMR ([D6]DMSO): d=1.30 (t, 3H, J=7.2 Hz, CH3), 2.00 (m, 2H,
CH2CH2O), 2.73 (t, 2H, J=7.0 Hz, CH2Ph), 4.06 (q, 2H, J=7.2 Hz,
CH2CH3), 4.22 (t, 2H, J=6.5 Hz, CH2O), 7.15–7.35 (m, 5H, HPh),
7.38 ppm (br s, 2H, NH2); elemental analysis: calcd for C16H18BrN5O:
C 51.08, H 4.82, N 18.61, found: C 51.13, H 4.89, N 18.58.
2-(Benzylthio)-8-bromo-9-ethyl-9H-purin-6-amine (19): Obtained
from 11 with a 50 min reaction time; purified by silica gel prepara-
tive TLC with elution with C6H12/EtOAc/CH3OH (59:40:1) ; yield 8%;
mp: not determined because a vitreous solid; 1H NMR ([D6]DMSO):
d=1.31 (t, 3H, J=7.2 Hz, CH2CH3), 4.14 (q, 2H, J=7.2 Hz, CH2CH3),
4.36 (s, 2H, CH2Ph), 7.19–7.59 ppm (m, 7H, HPh and NH2); elemen-
tal analysis: calcd for C14H14BrN5S: C 46.16, H 3.87, N 19.23, found:
C 46.68, H 3.95, N 19.17.
8-Bromo-9-ethyl-2-(phenethylthio)-9H-purin-6-amine (20): Ob-
tained from 12 with a 40 min reaction time; purified by silica gel
preparative TLC with elution with EtOAc/C6H12/CH3OH (60:35:5) ;
yield 18%; mp: 124–126 8C; 1H NMR ([D6]DMSO): d=1.34 (t, 3H, J=
7.2 Hz, CH2CH3), 2.98 (m, 2H, CH2S), 3.29 (m, 2H, CH2Ph), 4.14 (q,
2H, J=7.2 Hz, CH2CH3), 7.19–7.33 (m, 5H, HPh), 7.47 ppm (br s, 2H,
NH2); elemental analysis: calcd for C15H16BrN5S: C 47.63, H 4.26, N
18.51, found: C 47.75, H 4.56, N 18.41.
Biological assays
Radioligand binding studies : The binding studies were performed
by following the procedures described earlier.[9a] In brief, mem-
branes for radioligand binding were prepared from CHO cells
stably transfected with human adenosine receptor subtypes in
a two-step procedure. In a first low-speed step (1000g), cell frag-
ments and nuclei were removed. The crude membrane fraction
was sedimented from the supernatant at 100000g. The mem-
brane pellet was resuspended in the buffer used for the respective
binding experiments, frozen in liquid nitrogen and stored at
80 8C. For the measurement of adenylyl cyclase activity, only one
high-speed centrifugation of the homogenate was used. The re-
sulting crude membrane pellet was resuspended in 50 mm tris(hy-
droxymethyl)aminomethane/HCl, pH 7.4, and immediately used for
the cyclase assay. For A1 AR binding, 1 nm [
3H]CCPA was used as
the radioligand, whereas 10 nm [3H]NECA was used for A2A AR and
1 nm [3H]HEMADO for A3A AR. Non-specific binding was deter-
mined in the presence of 1 mm theophylline (A1 AR) or 100 mm
(A2A and A3 AR). Ki values from competition experiments were cal-
culated with the program SCTFIT.[22] Radioligand binding at the A2B
AR is problematic because no high-affinity ligand is available for
this subtype. Therefore, inhibition of NECA-stimulated adenylyl cy-
clase activity was determined as a measurement of affinity of the
compounds. IC50 values from these experiments were converted
into Ki values with the Cheng and Prusoff equation.
[23]
Functional assays at the A2A AR : The performed GloSensor cAMP
assay is a new non-radioactive method that offers a simple and
powerful approach to monitor G-protein coupled receptor (GPCR)
activity through change in the intracellular cAMP concentration.
The assay uses a mutant form of Photinus pyralis luciferase into
which a cAMP binding protein moiety has been inserted. The bind-
ing with cAMP triggers a biosensor conformation change that
leads to an increase of light output and allows evaluation of the
activity of ligands at the receptor under study. After pre-equilibra-
tion with a substrate, cells stably expressing the receptor of inter-
est and, transiently, the biosensor can be used to evaluate the
GPCR function, which enables easy kinetic measurements of cAMP
accumulation or turnover in living cells.
Cell culture : CHO cells stably expressing human A2A AR were grown
adherently and maintained in Dulbecco’s modified Eagle’s medium
with nutrient mixture F12 (DMEM/F12 with phenol red), supple-
mented with 10% fetal bovine serum (FBS), 100 UmL1 penicillin,
100 mgmL1 streptomycin, 2.5 mgmL1 amphotericin, 1 mm sodium
pyruvate and 0.1 mgmL1 Geneticin (G418), at 37 8C and aerated
with 5% CO2:95% O2. Cells were grown to approximately 70–80%
confluence and transient transfection with plasmid encoding the
biosensor was performed.
GloSensor cAMP assay : Cells were harvested in CO2-independent
medium and were counted in a Neubauer chamber. The desired
number of cells was incubated in equilibration medium containing
a 3% v/v GloSensor cAMP reagent stock solution, 10% FBS, and
87% CO2 independent medium. After 2 h of incubation, the cells
were dispensed in the wells of a 384-well plate and, when
a steady-state basal signal was obtained, the NECA referent agonist
or the understudy compounds, at different concentrations, were
added. The new synthesised compounds did not produce stimula-
tion of cAMP, so they were evaluated as antagonists. The antago-
nist profile was evaluated by assessing their ability to counteract
an agonist-induced increase of cAMP accumulation. The cells were
incubated in the reaction medium (10 min at room temperature)
with different understudy molecule concentrations and then treat-
ed with NECA. After 10 min, various luminescence reads were per-
formed at different incubation times.
Statistical analysis : Responses were expressed as a percentage of
the maximal relative luminescence units (RLU). Concentration–re-
sponse curves were fitted by a nonlinear regression with the
Prism 4.0 programme (GraphPAD Software, San Diego, CA, USA). To
quantify the NECA agonist potency, the EC50 value was calculated.
The EC50 value is the concentration of agonists required to produce
50% of the maximum effect. To evaluate the antagonist profile, the
IC50 values were determined. The IC50 value is the concentration of
antagonists that produces 50% inhibition of the agonist effect.
Each concentration was tested five times in triplicate and the
values are given as the mean  standard error.
Molecular modelling
General : Homology modelling and energy minimisation were car-
ried out with the MOE (version 2010.10) suite.[14] All ligand struc-
tures were optimised by using RHF/AM1 semiempirical calculations
and the software package MOPAC implemented in MOE was uti-
lised for these calculations.[15]
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Refinement of the human A2A AR structures : Two crystal struc-
tures of the human A2A AR in complex with ZM241385 were re-
trieved from the Protein Data Bank (http://www.rcsb.org; PDB ID:
3EML at 2.6  resolution and PDB ID: 4EIY at 1.8  resolution[13]).
The 3EML crystal structure was re-modelled firstly by removing the
T4L external segment and secondly by performing a building of
missing receptor regions (that is, missing sections of the EL2 or IL3
domains). The Homology Modelling tool of the MOE suite was em-
ployed. In detail, the boundaries identified from the used A2A AR X-
ray crystal structure were applied and the missing loop domains
were built by the loop search method implemented in the MOE
suite. Once the heavy atoms were modelled, all hydrogen atoms
were added, and the protein coordinates were then minimised
with the MOE suite by using the AMBER99 force field.[24] The mini-
misations were performed by steepest descent steps followed by
conjugate gradient minimisation until the root mean square gradi-
ent of the potential energy was less than 0.05 kJmol11. The reli-
ability and quality of the model were checked with the Protein Ge-
ometry Monitor application within the MOE suite, which provides
a variety of stereochemical measurements for inspection of the
structure quality in a given protein, such as backbone bond
lengths, angles and dihedrals, Ramachandran f–y dihedral plots
and side-chain–rotamer and non-bonded contact qualities. The
4EIY crystal structure was used in its original form, to which all hy-
drogen atoms were added within the MOE suite.
Homology modelling of the human A1 AR structure : A homology
model of the human A1 AR was built by using the 4EIY A2A AR crys-
tal structure (see above for details) as a template. A multiple align-
ment of the AR primary sequences was built within the MOE suite
as a preliminary step. The boundaries identified from the used X-
ray crystal structure of A2A AR were then applied for the corre-
sponding sequences of the TM helices of the A1 AR. The missing
loop domains were built by the loop search method implemented
in the MOE suite. Hydrogen atom addition and energy minimisa-
tion steps were made as described above for the 3EML A2A AR re-
modelling stage.
Molecular docking analysis : All compound structures were
docked into the binding site of the A2A AR by using AutoDock 4.2.6
software and the PyRx interface.[16] The Lamarckian genetic algo-
rithm was employed for this analysis with the following settings:
50 runs for each ligand, 2500000 as the maximum number of
energy evaluations, 27000 as the maximum number of genera-
tions, 0.02 as the rate of gene mutation and 0.8 as the rate of
crossover. The grid box was set with 50, 50 and 50 points in the x,
y and z directions, respectively, with the default grid spacing of
0.375 . This protocol was also used for the docking of a selected
group of ligands at the A1 AR.
Post-docking analysis and residue interaction analysis : The inter-
actions between the ligands and the receptor binding site were
analysed by using the IF-E 6.0 tool that is retrievable at the SVL ex-
change service (Chemical Computing Group, Inc. ; SVL exchange:
svl.chemcomp.com). The program calculates and displays the
atomic and residue interaction forces as 3D vectors. It also calcu-
lates the per-residue interaction energies, for which negative and
positive energy values are associated to favourable and unfavoura-
ble interactions, respectively. For each AR subtype, a shell of resi-
dues contained within a 10  distance from the ligand was consid-
ered for this analysis.
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The Length and Flexibility of the 2-
Substituent of 9-Ethyladenine
Derivatives Modulate Affinity and
Selectivity for the Human A2A
Adenosine Receptor
Size matters: Substituted 9-ethylade-
nine derivatives were synthesised and
tested for affinity to the human A2A ade-
nosine receptor. The new adenine deriv-
atives behave as A2A adenosine receptor
antagonists with half-maximal inhibitory
concentration values in the nanomolar
range. Molecular modelling studies pro-
vide a description of the possible bind-
ing mode of the compounds and an in-
terpretation of the affinity data.
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